PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportslupus nephritis
MeSH D008181 - lupus nephritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D008180:Systemic lupus erythematosus
$
Success rate
D005921:Glomerulonephritis
D008181: 
Lupus nephritis
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCyclophosphamide Neosar  1993-04-29   
Dr Reddys LaboratoriesCyclophosphamide Cyclophosphamide 2036-02-15 2020-07-30   
CiplaCyclophosphamide Cyclophosphamide  2019-01-18   
Alembic PharmaceuticalsCyclophosphamide Cyclophosphamide  2022-11-10   
Amneal PharmaceuticalsCyclophosphamide Cyclophosphamide  2018-05-25   
ANI PharmaceuticalsCyclophosphamide Cyclophosphamide  2018-03-19   
Hikma PharmaceuticalsCyclophosphamide Cyclophosphamide  2013-09-16   
Roxane LaboratoriesCyclophosphamide Cyclophosphamide  1999-08-17   
Aurinia PharmaceuticalsVoclosporin Lupkynis 2025-10-17 2021-01-22   
Eugia Pharma SpecialtiesCyclophosphamide Cyclophosphamide 2035-06-26 2021-08-25   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
63%
5/8
Phase 2
62%
28/45
Phase 3
34%
14/41
Approved: 3Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Baxter
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use